Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study

Similar Items

• Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure
  od: Mebazaa, A, i dr.
  Izdano: (2004)
• Newer treatments for decompensated heart failure: focus on levosimendan
  od: Follath, Ferenc
  Izdano: (2009)
• Effect of levosimendan treatment on length of hospital and intensive care stay in the REVIVE I study
  od: Johansson, S, i dr.
  Izdano: (2004)
• The ADHERE classification and regression tree model overestimates mortality rates in clinical trials: results from REVIVE I & II
  od: Thakkar, R, i dr.
  Izdano: (2007)
• Levosimendan Plus Dobutamine in Acute Decompensated Heart Failure Refractory to Dobutamine
  od: Juguet, William, i dr.
  Izdano: (2020)